
MOLECULAR CHARACTERIZATION OF
IRANIAN PATIENTS WITH INHERITED
COAGULATION FACTOR VII DEFICIENCY Shahbazi S1,*, Mahdian R2, Karimi K3, Mashayekhi A1 *Corresponding Author: Dr. Shirin Shahbazi, Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat
Modares University, Al-e-Ahmad and Chamran Cross, POB 14115-111Tehran, Iran. Tel: +98-21-82-884-556. Fax: +98-21-
82-884-555. E-mail: sh.shahbazi@modares.ac.ir page: 19
|
INTRODUCTION
Coagulation factor VII (FVII) is a vitamin K-dependent
serine protease that has a key role in the initiation of the
coagulation cascade. This factor circulates in the blood at a
concentration of 0.5 μg/mL and its severe reduction leads to
rare autosomal recessive bleeding disorder, FVII deficiency
[1,2]. The F7 gene maps to the long arm of chromosome
13 (13q34) and contains nine exons [1,3]. It is expressed
as two major transcripts, A and B, each ~3.1 kb long, that
encode polypeptides of 466 and 444 residues, respectively
[4]. The pre proteins are synthesized with either 60 or 38
amino acid leader sequences that yield a unique mature
single chain protein of 406 amino acids with a molecular
weight of ~50 kDa. Exons 1a, 1b and a fraction of exon 2
encode the leader sequences, the rest of exon 2 and exons
3 to 8 encode the mature protein [5]. Upon blood vessel injury,
tissue factor is exposed to the circulation and interacts
with FVII and activates it by cleavage between Arg152 and
Ile153. The activated FVII (FVIIa) consists of a 254-residue
heavy chain that contains a catalytic domain and is linked
by a disulfide bond to a 152-residue light chain that contains
two epidermal growth factor-like (EGF-like) domains [6].
The most common FVII deficiency symptoms consist
of soft tissue, mucocutaneous, joint and gastrointestinal
hemorrhage. The hereditary form of the disease shows
considerable phenotypic heterogeneity ranging from lethal
to mild or even asymptomatic types. As a result, prevalence
and incidence of FVII deficiency is not entirely determined
[7]. Studies show that the incidence of clinically significant
FVII deficiencies is estimated to be 1/500,000 [8]. However,
the disease is more frequent where consanguineous
marriages are commonplace [9]. The severity of hemorrhagic
symptoms is not directly related to the level of
plasma FVII coagulant activity [2,10]. In a study on 717
patients, Herrmann et al. [11] reported that about 60.0% of FVII deficient patients were asymptomatic who were
diagnosed following an abnormal prothrombin time (PT)
test. They also mentioned that the causative mutations
responsible for FVII deficiency are spread throughout the
F7 gene with no well-defined hot-spots. More than 250
mutations have been reported with FVII deficiency with
missense mutations as the most frequent type. Exon 8 is the
largest exon of the F7 gene that accommodates the highest
number of mutations [12]. The most severe cases are
either homozygous or compound heterozygous resulting
in FVII:C levels less than 2.0% of normal. Occasionally,
heterozygous carriers display hemorrhagic symptoms that
can be severe in rare cases. Recently, a heterozygous patient
was reported with severe spontaneous intra cranial
bleeding. He was a previously healthy 19-year-old patient,
without any reported hemorrhagic symptoms, even following
tonsillectomy in childhood [13].
We here report on the characterization of the mutations
in eight patients from eight unrelated families in Iran.
We also intended to elucidate the effect of each mutation
on their corresponding mRNA expression.
|
|
|
|



 |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|
|